Life Sciences: Solutions for Drug Development

Freeslate has a long history of successfully creating high throughput research solutions for both large- and small-molecule drug development.

The traditional venue for high throughput approaches has focused on drug discovery, where simple experiments can be designed to give "yes/no" screening indicators. But drug development typically requires more complex sample handling and rich data sets from a variety of sources to come to good conclusions.

To overcome the hurdles required to commercialize a drug, scientists need solid directional information early in the drug development process. However, limitations on material availability and pressure to reduce R&D costs make building comprehensive data sets challenging.

Many of these issues have shifted focus away from discovery and toward development and manufacturing where companies can realize a more direct return on investment. This is Freeslate's focus.

These are just a few of the companies that have realized value in working with us:

• Merck used Freeslate technologies to save more than $70 million in material cost over five years and won the Astra Zeneca IChemE Award for Excellence in Green Chemistry.
• Eli Lilly used Freeslate solutions to achieve a 90% reduction in testing time required for scientists to submit an NDA, resulting in a 3x-6x increase in productivity.
• Bristol-Myers Squibb was able to apply Freeslate technology to the management of its crystallization and solubility testing capacity, increasing the efficiency of its core testing facility by 10x.

Click here to learn more about our solutions for Life Sciences and how they can help you deliver step-change gains in your R&D.